{"id":4133,"date":"2026-11-05T09:00:00","date_gmt":"2026-11-05T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=4133"},"modified":"2026-11-07T16:07:56","modified_gmt":"2026-11-07T20:07:56","slug":"sarepta-closes-envision-enrollment-and-will-analyze-blinded-data","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=4133","title":{"rendered":"Sarepta Closes ENVISION Enrollment and Will Analyze Blinded Data"},"content":{"rendered":"<p><img fetchpriority=\"high\" decoding=\"async\" width=\"768\" height=\"768\" src=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261106_Sarepta_Therapeutics_Therapeutic_Indications-768x768.png\" alt=\"\" class=\"attachment-medium_large size-medium_large wp-image-4137\" srcset=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261106_Sarepta_Therapeutics_Therapeutic_Indications-768x768.png 768w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261106_Sarepta_Therapeutics_Therapeutic_Indications-300x300.png 300w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261106_Sarepta_Therapeutics_Therapeutic_Indications-1024x1024.png 1024w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261106_Sarepta_Therapeutics_Therapeutic_Indications-150x150.png 150w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261106_Sarepta_Therapeutics_Therapeutic_Indications.png 1254w\" sizes=\"(max-width: 768px) 100vw, 768px\" \/><\/p>\n<p><strong>Company<\/strong><\/p>\n<p>Sarepta Therapeutics<\/p>\n<p><strong>Event Type<\/strong><\/p>\n<p>Clinical development update<\/p>\n<p><strong>Modality<\/strong><\/p>\n<p>AAVrh74 gene therapy<\/p>\n<p><strong>Asset<\/strong><\/p>\n<p>Elevidys (delandistrogene moxeparvovec)<\/p>\n<p><strong>Target<\/strong><\/p>\n<p>DMD (microdystrophin)<\/p>\n<p><strong>Disease Area<\/strong><\/p>\n<p>Duchenne muscular dystrophy<\/p>\n<h4>Summary<\/h4>\n<p>Sarepta said November 5 it will not reopen enrollment in Phase 3 ENVISION, which studied Elevidys in nonambulatory and late-ambulatory Duchenne muscular dystrophy and has been on global clinical hold since 2025. It will analyze the blinded Part 1 data from 90 enrolled participants. This is a development-path change, not a new efficacy result.<\/p>\n<p>The cohort comprised 64 nonambulatory and 26 late-ambulatory participants across 14 countries. Sarepta says a restart would need a changed design incorporating sirolimus plus corticosteroids for nonambulatory patients, complicating interpretation against original assignments. ENDEAVOR Cohort 8 continues to test this prophylactic immunosuppression approach; Sarepta anticipates FDA discussion in early 2027.<\/p>\n<h4>Deep Analysis<\/h4>\n<p><strong>Interpretation A:<\/strong> closing enrollment preserves interpretability of an already randomized dataset and avoids combining incompatible regimens. The design concern supports this. Counterargument: the sample may be underpowered for clinically decisive subgroup conclusions.<\/p>\n<p><strong>Interpretation B:<\/strong> the halt and safety-management changes narrow the route to nonambulatory expansion. The ongoing hold supports caution; ENDEAVOR could still establish a viable amended path. Blinded functional outcomes, liver injury, exposure to sirolimus, follow-up and regulator feedback will distinguish these possibilities.<\/p>\n<h4>Company and Product Background<\/h4>\n<p>Elevidys is an AAVrh74 gene-transfer product expressing a shortened microdystrophin in Duchenne muscular dystrophy, a progressive X-linked muscle disease caused by pathogenic DMD variants. Nonambulatory use has faced separate safety and regulatory constraints.<\/p>\n<h4>Signal Extraction<\/h4>\n<ul>\n<li>The company gave a concrete design rationale.<\/li>\n<li>It did not disclose a new adverse event causing this decision, nor did it announce cancellation of all nonambulatory research.<\/li>\n<li>Treatment of placebo participants remains conditional on safety, data monitoring and regulatory authorization.<\/li>\n<\/ul>\n<h4>InSilens Take<\/h4>\n<p>ENVISION no longer provides a straightforward enrollment route. The existing randomized data and sirolimus safety findings are the next evidence, with no outcome inference warranted today.<\/p>\n<h4>Signal Assessment<\/h4>\n<p>Signal Importance: 5 of 5. Signal Direction: negative for the original trial path, uncertain for drug benefit. Confidence in Facts: high. Confidence in Interpretation: moderate-low until blinded outcomes and FDA feedback.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sarepta said November 5 it will not reopen enrollment in Phase 3 ENVISION, which studied Elevidys in nonambulatory and late-ambulatory Duchenne muscular dystrophy and has been on global clinical hold since 2025. It will&#8230;<\/p>\n","protected":false},"author":1,"featured_media":4137,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[84,1407,207],"class_list":["post-4133","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-therapeutic-indication","tag-duchenne-muscular-dystrophy","tag-elevidys","tag-sarepta-therapeutics"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4133","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4133"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4133\/revisions"}],"predecessor-version":[{"id":4155,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4133\/revisions\/4155"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/4137"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4133"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4133"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4133"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}